Zymeworks has dosed the first patient in its Phase I clinical trial of ZW191, an investigational therapy, aimed at treating advanced solid tumors that express folate receptor-α (FRα).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,